ICU Key Statistics, Chart & Performance
The current stock price of ICU is 0.2561 USD. In the past month the price decreased by -15.87%. In the past year, price decreased by -87.45%.
ICU Latest News, Press Relases and Analysis
ICU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.02 | 217.08B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.11 | 204.83B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.56 | 142.40B | ||
| SYK | STRYKER CORP | 26.9 | 135.46B | ||
| BDX | BECTON DICKINSON AND CO | 13.62 | 56.04B | ||
| IDXX | IDEXX LABORATORIES INC | 54.6 | 54.98B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.79 | 50.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.22 | 38.09B | ||
| RMD | RESMED INC | 24.72 | 35.73B | ||
| DXCM | DEXCOM INC | 36.33 | 26.35B | ||
| PODD | INSULET CORP | 63.16 | 20.31B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.22 | 17.99B |
Related stock screener links
About ICU
Company Profile
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Company Info
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 19
Phone: 18444278100
SEASTAR MEDICAL HOLDING CORP / ICU FAQ
Can you describe the business of SEASTAR MEDICAL HOLDING CORP?
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
What is the stock price of SEASTAR MEDICAL HOLDING CORP today?
The current stock price of ICU is 0.2561 USD. The price increased by 5.83% in the last trading session.
Does SEASTAR MEDICAL HOLDING CORP pay dividends?
ICU does not pay a dividend.
What is the ChartMill rating of SEASTAR MEDICAL HOLDING CORP stock?
ICU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in SEASTAR MEDICAL HOLDING CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ICU.
How many employees does SEASTAR MEDICAL HOLDING CORP have?
SEASTAR MEDICAL HOLDING CORP (ICU) currently has 19 employees.
What is SEASTAR MEDICAL HOLDING CORP worth?
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 9.23M USD. This makes ICU a Nano Cap stock.
ICU Technical Analysis
ICU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICU. ICU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ICU Financial Highlights
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 86.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.99% | ||
| ROE | -119.2% | ||
| Debt/Equity | 0 |
ICU Forecast & Estimates
5 analysts have analysed ICU and the average price target is 1.02 USD. This implies a price increase of 298.28% is expected in the next year compared to the current price of 0.2561.
For the next year, analysts expect an EPS growth of 91.82% and a revenue growth 385.51% for ICU